We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.
- Authors
Massaro, Fulvio; Andreozzi, Fabio; Abrassart, Tom; Castiaux, Julie; Massa, Hanne; Rizzo, Ornella; Vercruyssen, Marie
- Abstract
Over the past three decades, the treatment of lymphoproliferative disorders has undergone profound changes, notably due to the increasing availability of innovative therapies with the potential to redefine clinical management paradigms. A major impact is related to the development of monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cell therapies. This review discusses the current landscape of clinical trials targeting various hematological malignancies, highlighting promising early-phase results and strategies to overcome resistance. Lymphoproliferative disorders encompass a range of conditions: while in Hodgkin lymphoma (HL) the goal is to reduce chemotherapy-related toxicity by integrating immunotherapy into the frontline setting, peripheral T cell lymphoma (PTCL) lacks effective targeted therapies. The review emphasizes a shifting therapeutic landscape towards precision medicine and treatment modalities that are less toxic yet more effective.
- Subjects
LYMPHOPROLIFERATIVE disorders; BISPECIFIC antibodies; HODGKIN'S disease; CHIMERIC antigen receptors; HEMATOLOGIC malignancies
- Publication
Biomedicines, 2024, Vol 12, Issue 5, p977
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines12050977